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Venezuelan equine encephalitis (VEE) is reemerging in 
Peru. VEE virus subtype ID in Peru has not been previously 
associated with severe disease manifestations. In 2006, 
VEE virus subtype ID was isolated from a boy with severe 
febrile disease and gastrointestinal bleeding; the strain con-
tained 2 mutations within the PE2 region.
V
enezuelan equine encephalitis (VEE) is a reemerging 
disease in the Amazon region of Peru; subtype ID is 
the subtype most commonly isolated from humans (1–3). 
Although the typical clinical presentations of VEE are neu-
rologic and febrile syndromes, in the Amazon region, the 
common presentation is a febrile syndrome with mild or no 
neurologic involvement (1–4). Human infections with VEE 
virus subtype IAB and IC produce more neurologic involve-
ment and result in mortality rates as high as 0.5% during 
epidemics; however, epidemics with these viruses have not 
been reported in South America for more than a decade 
(5–7). During past epidemics, most neurologic disease and 
fatal cases were in children and elderly persons (8,9).
In 2006, an outbreak of febrile disease occurred 
in Jeberos, a rural Amazonian community in Loreto 
Peru, located 14 hours, by river, from Yurimaguas, Peru 
(Figure 1). Although VEE cases had been reported pre-
viously in Yurimaguas (T. Kochel, P.V. Aguilar, unpub. 
data), they had not been reported in Jeberos. We describe 
here the clinical manifestation of VEE subtype ID in a boy 
from Jeberos. The boy had severe disease; upper gastroin-
testinal bleeding; and neurologic, renal, and liver complica-
tions. He responded to supportive therapy.
The Case
On January 9, 2006, a 3-year-old boy from Jeberos 
was admitted to the Hospital Santa Gema in Yurimaguas. 
Three days before hospitalization, he had fever, chills, and 
malaise. Two days before hospitalization, the symptoms 
persisted and the boy was brought by his parents to the 
Health Center of Jeberos, where he received antipyretic 
medication (acetaminophen and the nonsteroidal antiin-
ﬂ  ammatory drug metamizole) for fever (40°C). One day 
before hospitalization, the boy became sleepy and irritable 
and had 2 episodes of vomiting followed by melena. The 
boy was then transferred by airplane to the Hospital Santa 
Gema in Yurimaguas. On the day of hospitalization, the 
boy was in poor general condition and had coffee-ground 
emesis (with blood clots) and melena. His temperature 
was 37ºC, blood pressure was 90/60 mm Hg, respiratory 
rate was 45 breaths/min, and heart rate was 132 beats/min. 
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Figure 1. Map of Peru showing Jeberos community in Yurimaguas, 
Loreto.He became somnolent, and marked paleness and scarce 
petechiae on both legs and severe dehydration were noted. 
No signs of jaundice, lymphadenopathy, or conjunctival 
bleeding were observed. No other signs were found in the 
thorax or cardiovascular system. Focal or meningeal signs 
and joint inﬂ  ammation were absent.
Laboratory test results were as follows: leukocytes 
12,200/mm3 (22% segmented cells, 0% bands, 75% lym-
phocytes, and 2% monocytes); platelets 122,000/mm3, he-
moglobin 56 g/L, and hematocrit 17%. Liver function was 
altered: alanine aminotransferase (ALT) 132 U/L, aspartate 
aminotransferase (AST) 140 U/L, serum albumin 2.1 g/dL, 
and total bilirubin 2.4 mg/dL (direct bilirubin 1.4 mg/dL). 
Serum creatinine was 2.2 mg/dL and, because of the boy’s 
age, was considered acute renal failure. Preliminary diag-
noses were febrile and hemorrhagic syndrome with severe 
dehydration and anemia. On the day of admission, January 
9, a blood sample was sent to the Naval Medical Research 
Center Detachment in Lima, Peru, and the National Insti-
tute of Health–Ministry of Health of Peru, for advanced 
analysis.
The boy was given supportive therapy, antimicrobial 
drugs, and blood replacement (200 mL). On January 10, his 
leukocyte count had dropped to 4,200/mm3 (26% segment-
ed, 14% bands, 56% lymphocytes, and 2% monocytes). 
After the transfusion, his hematocrit was 25%; his plate-
let count was 108,000/mm3 in the morning and decreased 
to 60,000/mm3 by night (Table). Test results for malaria 
(blood smear), agglutinins for typhoid fever, and surface 
antigen of hepatitis B virus were negative. The boy was 
hydrated and afebrile, but the melena and coffee-ground 
vomiting (with blood clots) persisted. On January 11, his 
hematocrit was 20% and platelet count was 91,000/mm3; 
he was still lethargic and the gastrointestinal bleeding per-
sisted. On January 12, he received a transfusion of 150 mL 
whole blood; however, he still showed neurologic involve-
ment (e.g., drowsiness, lethargy, confusion) and neck stiff-
ness. On January 16, the boy’s condition improved and the 
gastrointestinal bleeding stopped. Liver and renal func-
tions returned to within normal limits: serum creatinine 
1.6 mg/dL, ALT 40 U/L, AST 18 U/L, urine volume 535 
mL/24 h, and urine protein 36 mg/24 h. The boy’s mental 
status improved progressively, and he was discharged on 
January 20.
VEE virus was isolated from serum culture in Vero 
cells. No other viruses were isolated in Vero or C6/36 
cells. A convalescent-phase sample obtained ≈2 weeks 
after symptom onset had a >4-fold higher titer than the 
acute-phase sample, according to a previously described 
immunoglobulin (Ig) M ELISA speciﬁ  c for VEE (2). The 
sample was IgM negative for other local arthropod-borne 
viruses such as dengue, yellow fever, Mayaro, Oropouche, 
and members of the group C complex. Genetic analyses 
using previously described methods further identiﬁ  ed the 
VEE strain as subtype ID, genotype Panama-Peru (1,4) 
(Figure 2). The strain was genetically similar to other strains 
isolated previously in Peru; however, 2 amino acid changes 
were observed within the envelope glycoprotein precur-
sor (PE2) region (H→Q, V→I). The National Institute of 
Health–Ministry of Health reported negative results for lep-
tospirosis and rickettsial diseases, according to IgM ELISA 
and indirect immunoﬂ  uorescent assay, respectively.
In February 2006, another case of VEE in a child was 
reported. A 10-year-old boy with similar clinical signs, 
including headache, vomiting, melena, and altered men-
tal status (somnolence and confusion) was admitted to the 
hospital in Yurimaguas. The boy, a resident of Esperanza 
village, Lagunas district, had visited the Aypena River near 
Jeberos. The acute-phase serum sample was positive for 
VEE virus by PCR; however, no virus was isolated in cell 
culture. A convalescent-phase sample, taken a week after 
onset of signs, was negative by VEE IgM ELISA; no ad-
ditional convalescent-phase sample was obtained from the 
patient. No epizootics were reported.
Conclusions
VEE virus subtype ID was isolated from a child with 
neurologic and severe hemorrhagic manifestations in the 
northern Peruvian jungle. During this episode, local health 
workers in Jeberos reported that they had evaluated at least 
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Table. Blood cell counts and hemoglobin values in a 3-year-old boy with Venezuelan equine encephalitis, Jeberos, Peru, January 
2006*
Leukocytes, % 
Neutrophils
Date/time of 
sample
collection
Platelets/
mm
3
Hematocrit,
%
Leukocytes/ 
mm
3 Bands Segmented Eosinophils Monocytes Lymphocytes
Hemoglobin,
g/L
Jan 9  122,000 17 12,900 0 22 2 2 76 56
Jan 10 
 4  h  108,000 25 4,200 14 26 2 2 56
 10  h  120,000 23 NM NM NM NM NM NM NM
 16  h  87,000 22 NM NM NM NM NM NM NM
 22  h  60,000 21 NM NM NM NM NM NM NM
Jan 11  91,000 20 NM NM NM NM NM NM NM
Jan 16  230,000 35 8,900 2 70 NM NM 28 NM
*NM, not measured. VEE and GI Bleeding, Child
5 cases with some hemorrhagic manifestations; however, 
no samples were obtained from those cases, and thus there 
is no deﬁ  nitive proof that the patients were infected with 
VEE virus.
The VEE strain isolated from the boy with conﬁ  rmed 
VEE contained 2 mutations within the PE2 region, which 
differed from other subtype ID strains from Peru. Nev-
ertheless, the contribution of these or any other possible 
mutations in the viral genome to the hemorrhagic mani-
festation observed in the patient remains unknown. Many 
questions remain about the effect of VEE virus in the Je-
beros community.
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Figure 2. Neighbor-joining phylogenetic tree of Venezuelan equine 
encephalitis virus complex based on partial sequence of the 
envelope glycoprotein precursor segment. The strain isolated from 
the 3-year-old boy with upper gastrointestinal bleeding, Jeberos, 
Peru, January 2006, is shown in boldface. Numbers indicate 
bootstrap values.